APA (7th ed.) Citation

Peng, J., Zhai, X., Liu, X., Huang, Z., Wang, Y., Wu, P., . . . Meng, X. Beyond first-line therapy: Efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression. Elsevier.

Chicago Style (17th ed.) Citation

Peng, Jianfeng, Xueying Zhai, Xiaomei Liu, Zhaoqin Huang, Yimeng Wang, Peizhu Wu, Ran Gao, and Xiangjiao Meng. Beyond First-line Therapy: Efficacy and Safety Outcomes of Continuing Immunotherapy in Extensive Stage Small Cell Lung Cancer After PD-L1 Inhibitor Progression. Elsevier.

MLA (9th ed.) Citation

Peng, Jianfeng, et al. Beyond First-line Therapy: Efficacy and Safety Outcomes of Continuing Immunotherapy in Extensive Stage Small Cell Lung Cancer After PD-L1 Inhibitor Progression. Elsevier.